December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

66.45 +0.08 (+0.12%)
Streaming Delayed Price Updated: 12:19 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
45 46 Next >
News headline image
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.
From DexCom, Inc.
Via Business Wire
News headline image
2 S&P 500 Stocks Worth Investigating and 1 to Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
Price Over Earnings Overview: DexCom ↗
 
Via Benzinga
News headline image
Forecasting The Future: 7 Analyst Projections For DexCom ↗
 
Via Benzinga
News headline image
Abbott, Dexcom Draw Retail Buzz As RFK Jr. Urges Americans To Embrace Health Wearables ↗
Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom. 
Via Stocktwits
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
Entegris, Herc, Enovis, Commercial Vehicle Group, and DexCom Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.4%, S&P 500 +1.0%) on hopes the reported ceasefire between Israel and Iran will hold. This de-escalation... 
Via StockStory
Topics Economy Government Stocks
News headline image
Top S&P500 movers in Tuesday's session ↗
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025
From DexCom, Inc.
Via Business Wire
News headline image
Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Expert Outlook: DexCom Through The Eyes Of 8 Analysts ↗
 
Via Benzinga
News headline image
Lifshitz Law PLLC Announces Investigations of Nano Nuclear Energy, Inc. (NASDAQ: NNE), Extreme Networks, Inc. (NASDAQ: EXTR), DexCom, Inc. (NASDAQ: DXCM), and Methode Electronics, Inc. (NYSE: MEI)
Via ACCESS Newswire
News headline image
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
From Johnson Fistel, PLLP
Via Business Wire
News headline image
1 Cash-Producing Stock on Our Buy List and 2 to Be Wary Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
DEXCOM INC (NASDAQ:DXCM) – A Strong Growth Stock with a Bullish Technical Setup ↗
DEXCOM INC (NASDAQ:DXCM) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities. 
Via Chartmill
News headline image
DEXCOM INC (NASDAQ:DXCM) - A Technical Breakout Candidate Worth Watching ↗
DEXCOM INC (NASDAQ:DXCM) shows strong technicals and a high-quality setup, making it a potential breakout candidate. The stock's consolidation and bullish signals suggest a possible upward move. 
Via Chartmill
News headline image
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges ↗
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
News headline image
2 Profitable Stocks on Our Watchlist and 1 to Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Topics Supply Chain
News headline image
Wednesday's session: top gainers and losers in the S&P500 index ↗
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
News headline image
Stay informed with the top movers within the S&P500 index on Wednesday. ↗
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Prediction: These 2 Stocks Will Beat the Market in the Next Decade ↗
Via The Motley Fool
Topics Government
News headline image
2 Momentum Stocks with Impressive Fundamentals and 1 to Avoid
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
News headline image
3 Big Reasons to Love DexCom (DXCM)
Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was partly thanks to its solid quarterly results, and... 
Via StockStory
Topics Government Stocks
News headline image
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants ↗
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants... 
Via Benzinga
News headline image
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook
Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be... 
Via StockStory
Topics Economy
News headline image
DXC Tech Stock Slides On Sour Guidance, But Retail's Happy As Q4 Results Top Estimates ↗
The company's bookings grew more than 20% for the second straight quarter, and the book-to-bill ratio exceeded one. 
Via Stocktwits
Topics Earnings
News headline image
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
From DexCom, Inc.
Via Business Wire
News headline image
1 Healthcare Stock with Exciting Potential and 2 to Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
News headline image
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
Dexcom's strong quarterly performance and innovative product pipeline signal continued leadership and expansion within the evolving diabetes technology market. 
Via MarketBeat
Topics Earnings
News headline image
What's Driving the Market Sentiment Around DexCom? ↗
 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.